Lifesci Capital Has Positive Outlook of ELVN FY2025 Earnings

Enliven Therapeutics, Inc. (NASDAQ:ELVN) – Investment analysts at Lifesci Capital upped their FY2025 EPS estimates for Enliven Therapeutics in a research report issued on Monday, March 17th. Lifesci Capital analyst S. Slutsky now forecasts that the company will post earnings of ($2.54) per share for the year, up from their prior estimate of ($2.57). The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($1.95) per share.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.07. The firm had revenue of $0.03 million for the quarter.

Separately, BTIG Research started coverage on shares of Enliven Therapeutics in a research note on Friday, December 13th. They set a “buy” rating and a $42.00 price target on the stock. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $38.25.

Enliven Therapeutics Stock Up 3.0 %

Shares of Enliven Therapeutics stock opened at $20.89 on Wednesday. Enliven Therapeutics has a 52-week low of $15.96 and a 52-week high of $30.03. The company’s 50-day simple moving average is $21.39 and its 200-day simple moving average is $23.78. The firm has a market cap of $1.02 billion, a price-to-earnings ratio of -10.99 and a beta of 1.04.

Institutional Trading of Enliven Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ELVN. Invesco Ltd. lifted its holdings in shares of Enliven Therapeutics by 3.5% in the fourth quarter. Invesco Ltd. now owns 15,072 shares of the company’s stock valued at $339,000 after purchasing an additional 508 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Enliven Therapeutics by 3.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,036 shares of the company’s stock valued at $451,000 after purchasing an additional 718 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock valued at $36,000 after purchasing an additional 1,114 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Enliven Therapeutics by 14.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company’s stock valued at $233,000 after purchasing an additional 1,275 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its holdings in shares of Enliven Therapeutics by 6.3% in the fourth quarter. MetLife Investment Management LLC now owns 21,746 shares of the company’s stock valued at $489,000 after purchasing an additional 1,285 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Insider Buying and Selling

In related news, CFO Benjamin Hohl sold 1,000 shares of the business’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $25.04, for a total transaction of $25,040.00. Following the sale, the chief financial officer now owns 13,000 shares of the company’s stock, valued at approximately $325,520. The trade was a 7.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Anish Patel sold 21,700 shares of the business’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $24.18, for a total transaction of $524,706.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 60,284 shares of company stock valued at $1,352,750. Corporate insiders own 29.20% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.